Abstract
AbstractBackgroundThe burden of obesity in the United States and in the Veterans Affairs (VA) population disproportionately affects minoritized individuals. Major advances in the treatment of obesity have emerged in the last decade, including incretin-based injectables like semaglutide, but it is not clear that they are being distributed equitably. We examined the role that race and ethnicity play in the receipt of a lifestyle change program, medications, and surgical treatment for obesity.MethodsWe analyzed data from patients with BMI ≥27 in the national VA Healthcare System from 2018-2022. We used multivariate logistic regression to evaluate the association between race/ethnicity (American Indian/Alaska Native [AI/AN], Asian/Native Hawaiian/Pacific Islander [NHOPI], Non- Hispanic Black, Hispanic/Latino, Non-Hispanic White) and use of weight loss interventions (VA lifestyle change program, medication prescriptions, bariatric surgery), adjusting for age, gender, comorbidities, and diagnosis year.ResultsAmong Veterans with BMI ≥27 (n=2,423,070), 38.8% had Class 1 obesity (BMI 30-34.9), 18.1% had Class 2 obesity (BMI 35-39.9), and 9.8% had Class 3 obesity (BMI>40), with significant differences by race/ethnicity (p<0.01). Across the cohort, 7.7% participated in the lifestyle change program, 7.9% received weight loss medications, and 0.1% underwent bariatric surgery. Compared to Non-Hispanic White patients, Veterans belonging to many racial/ethnic minority groups were more likely to participate in the lifestyle change program (Asian/NHOPI Veterans, 1.12 [95% CI 1.06-1.19]; Non-Hispanic Black Veterans, adj OR 1.24 [95% confidence interval [CI] 1.22-1.26]; Hispanic/Latino Veterans, adj OR 1.17 [95% CI 1.14-1.20]) and less likely to receive weight loss medications (AI/AN Veterans, adj OR 0.84 [95% CI 0.77-0.92]; Asian/NHOPI Veterans: adj OR 0.94 [95% CI 0.89-0.999]; Non-Hispanic Black Veterans, adj OR 0.75 [95% CI 0.74-0.76]; Hispanic/Latino Veterans, adj OR 0.94 [95% CI 0.91-0.97]). Black Veterans were also less likely to undergo bariatric surgery (adj OR 0.79 [95% CI 0.69-0.89]).ConclusionsAmong Veterans with obesity, rates of treatment across all modalities are low. Inequities in treatment approach by race/ethnicity suggest areas for focused intervention to close gaps in care.
Publisher
Cold Spring Harbor Laboratory
Reference50 articles.
1. Office of the Commissioner of the FDA. FDA. FDA; 2021 [cited 2024 Jan 12]. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
2. Office of the Commissioner of the FDA. FDA. 2023 [cited 2024 Jan 12]. FDA Approves New Medication for Chronic Weight Management. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
3. Stierman B , Afful J , Carroll MD , Chen TC , Davy O , Fink S , et al. National Health and Nutrition Examination Survey 2017–March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. Natl Health Stat Rep. 2021 Jun 14;(158).
4. Office of the Surgeon General (US), Office of Disease Prevention and Health Promotion (US), Centers for Disease Control and Prevention (US), National Institutes of Health (US). Section 1: Overweight and Obesity as Public Health Problems in America. In: The Surgeon General’s Call To Action To Prevent and Decrease Overweight and Obesity [Internet]. Office of the Surgeon General (US); 2001 [cited 2024 Jan 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK44210/
5. Health Effects of Overweight and Obesity in 195 Countries over 25 Years